Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial

Diabetes, Obesity and Metabolism

Volumn 14, Issue 5, 2012, Pages 464-469

  van Dieren, S ^a,b   Czernichow, S ^c   Chalmers, J ^a   Kengne, A P ^a,b,d   de Galan, B E ^e   Poulter, N ^f   Woodward, M ^a   Beulens, J W J ^b   Grobbee, D E ^b   van der Schouw, Y T ^b   Zoungas, S ^a,g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g MONASH UNIVERSITY   (Australia)

Author keywords

Antidiabetic drug; Clinical trial; Diabetes complications; Diabetes mellitus; Glycaemic control; Obesity therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLICLAZIDE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; THIAZOLE;

ADULT; AGE; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC PATIENT; ETHNICITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84859440269     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01556.x     Document Type: Article

References (23)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: estimates for the year and projections for 2030. Diabetes Care 2000; 27: 1047-1053.
2. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
3. Strandberg TE, Strandberg AY, Salomaa VV et al. Explaining the obesity paradox: cardiovascular risk, weight change, and mortality during long-term follow-up in men. Eur Heart J 2009; 30: 1720-1727.
4. Czernichow S, Kengne AP, Huxley RR et al. Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from advance. Eur J Cardiovasc Prev Rehabil 2011; 318: 312-319.
5. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
6. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
7. Hsu WC. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J 2009; 102: 67-76.
8. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S18-S24.
9. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
10. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
11. Patel A, Macmahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
12. Patel A, Macmahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
13. Nathan DM. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the diabetes control and complications trial. Diabetes Care 2001; 24: 1711-1721.
14. Feldstein AC, Nichols GA, Smith DH, Rosales AG, Perrin N. Weight change and glycemic control after diagnosis of type 2 diabetes. J Gen Intern Med 2008; 23: 1339-1345.
15. Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
16. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes, Obes Metab 2007; 9: 799-812.
17. Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc 2009; 49(Suppl. 1): S3-S9.
18. Krentz AJ. Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. Curr Med Res Opin 2008; 24: 401-417.
19. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
20. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J Diabetes Complicat 2002; 16: 123-132.
21. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63-71.
22. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
23. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.